Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients

Watson, Maggie; Buck, Georgina; Wheatley, Keith; Homewood, J.; Goldstone, Anthony H.; Rees, J. K. H.; Burnett, Alan Kenneth

doi:10.1016/s0959-8049(03)00628-2

Cited by 86 publications

(82 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these results were conflicting, and few have controlled confounding backgrounds. [21][22][23][24][25][26][27] In a longitudinal study that assessed the QOL in patients treated with allo-HCT, autologous HCT or chemotherapy, the allo-HCT group had higher scores in global QOL, fatigue and sleep disturbance compared with the other two groups. 21 The results may be confounded by the difference in populations between the treatment groups: the allo-HCT group included only leukemia patients and the autologous HCT/chemotherapy groups included only lymphoma patients.…”

Section: Qol Estimates Provided By Patientsmentioning

confidence: 99%

“…Three studies that included AML in remission reported worse QOL in patients who received Quality of life after treatment for acute leukemia S Kurosawa et al allo-HCT. 24,25,27 Zittoun et al 27 performed a cross-sectional study and showed that physical, role functioning, sexual functioning and overall QOL were significantly lower after allo-HCT than after chemotherapy. In more recent cross-sectional studies with a larger number of AML patients, allo-HCT had an adverse impact on the QOL in many of the dimensions in EORTC QLQ-C30.…”

Section: Qol Estimates Provided By Patientsmentioning

confidence: 99%

“…In more recent cross-sectional studies with a larger number of AML patients, allo-HCT had an adverse impact on the QOL in many of the dimensions in EORTC QLQ-C30. 24,25 We used a comprehensive scale (SF-36) and a disease-specific scale (FACT-Leukemia), which enabled us to assess both QOL in comparison with those in general population, and QOL specifically associated with leukemia patients. In contrast, the EORTC QLQ-C30 was used in the three studies that reported a worse QOL in the allo-HCT group.…”

Section: Qol Estimates Provided By Patientsmentioning

confidence: 99%

“…[12][13][14][15][16][17][18][19][20] Several studies have compared patient-reported QOL between allo-HCT and chemotherapy. [21][22][23][24][25][26][27] Zittoun et al 27 performed a cross-sectional study of the EORTC-GIMEMA AML 8 A trial and compare QOL after allo-HCT, autologous HCT and chemotherapy, and reported that allo-HCT had an adverse impact on the QOL. More recent cross-sectional studies 24,25 applied the EORTC Quality of Life Core Questionnaire (QLQ-C30) to a larger number of AML patients, and reported that patients who received allo-HCT had a significantly worse QOL.…”

Section: Introductionmentioning

confidence: 99%

“…[21][22][23][24][25][26][27] Zittoun et al 27 performed a cross-sectional study of the EORTC-GIMEMA AML 8 A trial and compare QOL after allo-HCT, autologous HCT and chemotherapy, and reported that allo-HCT had an adverse impact on the QOL. More recent cross-sectional studies 24,25 applied the EORTC Quality of Life Core Questionnaire (QLQ-C30) to a larger number of AML patients, and reported that patients who received allo-HCT had a significantly worse QOL. However, other studies have reported inconsistent results, because of heterogeneous diseases, a small number of patients included, and different types of questionnaires used in the studies.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia

Kurosawa¹,

Yamaguchi

Mori

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

When discussing treatment options for patients with acute leukemia, it is important to acknowledge the impact of allogeneic hematopoietic cell transplantation (allo-HCT) or chemotherapy on quality of life (QOL). We performed a cross-sectional questionnaire study that administered SF-36, FACT-Leukemia and EuroQOL5D to 524 acute leukemia survivors, to compare patientreported QOL between chemotherapy and allo-HCT, and to elucidate predictors of QOL. Patients who received chemotherapy alone had a better physical QOL than those who received allo-HCT. On the other hand, the allo-HCT group reported a better mental QOL. In the comparison of QOL in the allo-HCT patients according to the presence of GVHD at survey, patients who had GVHD symptoms experienced statistically and clinically significantly worse QOL than those who did not. In the allo-HCT patients without GVHD, the physical QOL was comparable to that in the chemotherapy patients, and they experienced significantly better mental and general QOL than the chemotherapy patients. GVHD and immunosuppressive drugs at survey were strongly associated with worse QOL after allo-HCT. In the chemotherapy group, a shorter time between treatment completion and survey was significantly associated with worse QOL. Further evaluation of QOL by a longitudinal assessment with quantitative and qualitative analyses are warranted.

show abstract